We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Angiotensin-converting Enzyme (ACE)

Angiotensin-converting enzyme (ACE) inhibitors block the peptidase that turns angiotensin I into angiotensin II. In 1956 the activity was described in plasma as a hypertensin-converting enzyme that generates the pressor peptide. ACE also inactivates bradykinin, so it connects the renin-angiotensin-aldosterone system (RAAS) with the kinin system. Molecular cloning in 1988 showed that somatic ACE carries two homologous domains, each with a putative active center. Carboxyalkanoyl and mercaptoalkanoyl amino acids, designed in 1977, set the structural pattern for most later inhibitors. Enalapril maleate, ramipril and perindopril erbumine are carboxylate-type prodrugs, whereas fosinopril sodium contains a phosphinate group and zofenopril calcium a protected thiol group.

1 Item

  • ME3221
    Cat. No.
    A42316
    CAS No.
    139958-16-0

    ME3221

    ME3221 is a selective angiotensin-converting enzyme (ACE) antagonist that effectively inhibits the pressor response to angiotensin II, demonstrating significant antihypertensive activity in both renal hypertensive rats and spontaneously hypertensive rats (SHR). Its administration results in sustained and stable reductions in blood pressure without impacting heart rate, making ME3221 a valuable tool for research into renal and essential hypertension. This compound is ideal for studying the mechanisms underlying hypertension and evaluating therapeutic strategies for cardiovascular disorders.

    In stock View Details
    1 mg
    $140.00
    5 mg
    $355.00
    All 4 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...